Amgen to Supreme Court: 180-Day Notification for Biosimilar Launch Must Come After FDA Approval

Amgen is calling on the U.S. Supreme Court to rule that biosimilar makers must wait six months after an FDA approval to market their therapy.
Source: Drug Industry Daily